跳至主要内容
临床试验/NCT00895791
NCT00895791撤回不适用

Comparison of Healing Responses After Treatment of Complex Bifurcation Lesions With the AXXESS Biolimus A9 Eluting Stent Versus Culotte Technique Using Everolimus-eluting Stents: an Optical Coherence Tomography Analysis.

Universitaire Ziekenhuizen KU Leuven1 个研究点 分布在 1 个国家开始时间: 2009年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
The primary endpoint is % stent strut coverage and % stent strut apposition, assessed with optical coherence tomography, at 9 months follow-up.

研究概览

简要总结

The aim of this study is to compare vessel healing at 9 months using OCT imaging for two different treatment techniques for treating bifurcation lesions. Quantitative assessment of OCT images will be used to assess re-endothelialization and quality of strut apposition to the vessel wall.

详细描述

Background: There is an ongoing controversy over the efficacy and safety of different bifurcation stenting techniques. Critical considerations are the rate of restenosis at the side branch ostium, and completeness of healing at sites of overlap of stent struts, which may affect the risk of stent thrombosis.

Methods: Patients with complex bifurcation lesions with involvement of a significant side branch requiring a stent are randomized into two treatment arms. The first group of 20 patients (group I) is treated with the AXXESS Biolimus A9 Bifurcation Stent System (Devax, Inc, Lake Forest CA), where additional everolimus-eluting Xience V stents (Abbott Vascular, Santa Clara, CA) are implanted into the distal main branch and the side branch as required. The second group of 20 patients (group II) is treated with the culotte technique using everolimus-eluting Xience V stents. Kissing balloon dilatation using non-compliant balloons will complete the index procedure in all cases. At 9 months, control angiography (with QCA using dedicated software) and OCT (of both main vessel and side branch) is performed.

Assessment of Results:

  1. EP: stent strut coverage and stent strut apposition, assessed with OCT at 9 months.
  2. EP: restenosis, restenosis at SB ostium, MACE, stent thrombosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patient older than 18 years
  • •Written informed consent available
  • •Patient eligible for percutaneous coronary intervention
  • •Patients with a de novo and true coronary bifurcation lesion (Medina classification (1,1,1), (1,0,1) or (0,1,1))
  • •Target reference vessel diameter measured by QCA: 2-4 mm
  • •Target lesion stenosis measured by QCA: > 70% - < 100%
  • •Patients willing to provide written informed consent prior to participation and willing and able to participate in all follow-up evaluations

排除标准

  • •Left ventricular ejection fraction of < 30%
  • •Impaired renal function (serum creatinine > 2.0 mg/dl)
  • •Previous and/or planned brachytherapy of target vessel
  • •Lesion of the left main trunk > 50%, unprotected
  • •Known allergies to antiplatelet, anticoagulation therapy, contrast media or everolimus
  • •Pregnant and/or breast-feeding females or females who intend to become pregnant (pregnancy test required)
  • •Patients with a life expectancy of less than one year
  • •Patient currently enrolled in other investigational device or drug trial
  • •Patient not able or willing to adhere to follow-up visits
  • •Patients who intend to have a major surgical intervention within 6 months of enrolment in the study
  • •Patient not able or willing to adhere to follow-up visits
  • •Patients who previously participated in this study

研究组 & 干预措施

1

Active Comparator

AXXESS Biolimus A9-eluting bifurcation stent

干预措施: AXXESS Biolimus A9-eluting bifurcation stent (Device)

2

Active Comparator

culotte stenting with use of 2 drug eluting stents

干预措施: culotte stenting (Xience V) (Device)

结局指标

主要结局

The primary endpoint is % stent strut coverage and % stent strut apposition, assessed with optical coherence tomography, at 9 months follow-up.

时间窗: 9 months

次要结局

  • Clinical outcome: Cumulative MACE rate at 1, 8, 9 and 12 months, yearly until 5 years. Separate rates will be provided for: cardiac death, non-fatal myocardial infarction, clinically driven TLR, TVR.(5 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验